Natural Resources for Human Health
eISSN: 2583-1194

Original Research

Received 25 May 2026
Revised 12 July 2026
Accepted 27 July 2026

Natural Resources for Human Health 2026, Vol. 6 (13s): 272–281

KEYWORDS:
Biomarkers in Cancer, Immunotherapy, Magnetic Resonance Imaging, Neoplasms, Precision Medicine, Radiopharmaceuticals

Advancing Oncology Through Emerging Pharmacological Therapies and Innovative Radiological Techniques: A Pathway to Personalized Diagnosis and Treatment

Dr. Tejshri Bansod [1]*, Dr. Sheetal Asutkar[2],

1*PG Scholar, Department of Shalyatantra, Mahatma Gandhi Ayurved Collage Hospital and Research Center, Salod (H), Datta Meghe Institute of Medical Sciences, Wardha 442001
2Head of Department [HOD], Department of Shalyatantra, Mahatma Gandhi Ayurved Collage Hospital and Research Center, Salod (H), Datta Meghe Institute of Medical Sciences, Wardha 442001
Corresponding author: Dr. Tejshri Bansod
teju18.bhombe@gmail.com

ABSTRACT:

Background: Oncology has been plagued by tumour heterogeneity, complex biology, and heterogeneity of response to therapy. Novel pharmacological therapies and radiological technology are revolutionizing cancer diagnosis and treatment practice and offering solutions to the problems. Novel pharmacological therapies like targeted therapy, immunotherapy, and radiopharmaceuticals now characterize oncology. At the same time, novel radiological technologies like imaging-based biomarkers, precision radiotherapy, and radiomics enhance diagnostic accuracy and enable personalized therapies.

Objective: The review attempts to chart the intersection of new pharmacological therapies and new radiological technologies in oncology and their ability to enhance diagnosis, treatment, and patient outcomes through personalized medicine.

Methods: We reviewed extensively recent literature, clinical trials, and technological innovations in the intersection of pharmacology and radiology in oncology. The text is on radiotheranostic, immuno-radiotherapy, and precision imaging method breakthroughs.

Results: Convergence of pharmacological agents with imaging modalities has been promising to improve cancer treatment efficacy, facilitate early diagnosis, accurate monitoring, and personalized treatment regimens. Breakthrough critical advances in radiopharmaceuticals and immuno-radiotherapy are discussed, emphasizing clinical applications.

Conclusion: The convergence of new pharmacological therapies and new radiological technologies is transforming the future of oncology. Further studies must be realized to overcome the existing limitations and reap the full benefit of personalized, targeted cancer therapy.

INTRODUCTION

Oncology is bound to be the most demanding and fast-evolving speciality of medicine, dealing with the diagnosis, therapy, and management of an enormous array of malignancies. Cancer, although a leading cause of death and illness across the globe, even in the present era, is a highly heterogeneous problem due to its heterogeneity, varying growth rates, and drug resistance (Astaraki et al., 2019). According to the World Health Organization, the annual number of cancer deaths is about 10 million, and this is a staggering projection of a rise in the rates of cancer incidence in the years to come. Cancer treatment has moved from conventional therapies like surgery, chemotherapy, and radiotherapy to newer, more targeted treatment regimens through the genetic and molecular identification of individual tumours (Baek et al., 2019).

Pharmacologic therapy is the backbone of cancer therapy in the current era. The trend in pharmacologic therapy has been toward target therapy, immunotherapy, and gene therapy (Bailly et al., 2016). These drugs, including immune checkpoint inhibitors and targeted monoclonal antibodies, have shown to be highly promising in enhancing patient outcomes by targeting the molecular basis of the cancer. The shift from using old, age-old, one-size-fits-all therapy to more molecular-profiling and patient-genetic-marker-specific therapies is revolutionizing cancer therapy. Next-generation agents in the pipeline will target the cancer cells even more specifically with fewer toxicities and with increased efficacy against recurred cancers (Blanc-Durand et al., 2020).

With the advancement of pharmacology, the use of radiological methods in oncology has progressed by leaps and bounds. Radiological imaging in the modalities of computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) has been the cornerstone of cancer staging, detection, and monitoring over the last two decades (Brown et al., 2010). More recent radiology technologies, however, such as radiotheranostics, are revolutionizing cancer therapy. Radiotheranostics combines targeted radiopharmaceuticals and imaging to deliver the same dose of therapy in a single visit, both for cancer detection and treatment. Radiomics, quantitative imaging analysis, can predict therapeutic response and response to therapy, enabling more personalized, data-driven therapy (Guaitoli et al., 2019).

In the last couple of years, there has been growing interest in the union of radiological techniques and pharmacological treatment in oncology. The new discipline of radiopharmacology combines the two, where pharmacological therapies are paired with radiopharmaceuticals to target cancer cells selectively. Radiolabeled drugs, such as in radiotheranostics, are being engineered to provide targeted radiation and improve the effectiveness of other cancer treatments. The dual treatment has the potential to minimize side effects and maximize therapeutic effect, a shift in paradigm in cancer therapy (Weissleder & Mahmood, 2001).

However, even with such promising advances, there are a few critical issues in the synergy of pharmacological and radiological methods. They are the use of highly individualized treatment regimens, optimization of drug delivery platforms, and the development of effective biomarkers for the prognosis of the therapeutic response (Thakur & Lentle, 2006). The technical and clinical challenge of combining these disciplines is overcoming technical and clinical hurdles, including targeting radiopharmaceuticals to the tumour microenvironment and reducing off-target toxicity (Zhong et al., 2021).

This review will critically evaluate the latest developments in integrating pharmacologic treatment and radiologic methods in oncology. From reflection on the latest clinical trials, preclinical outcomes, and new treatments, this review will delineate the promise of integrating the techniques to advance patient diagnosis, treatment, and care. The objective is to describe in detail how integrating radiology and pharmacology will reshape oncology's future, maximizing individualization of treatment and re-engineering cancer therapy.

LITERATURE REVIEW

The intersection of pharmacological treatment and radiological imaging has been promising for improving oncology treatments. Personalized oncology, especially in interventional radiology, is intended to individualize treatment to the patient's profile, but it is still difficult to fully implement these strategies in clinical practice (Abi-Jaoudeh et al., 2013). Artificial intelligence (AI) and hybrid imaging techniques are transforming personalized medicine, improving diagnostic accuracy and treatment specificity (Sollini et al., 2020). Targeted cancer therapies have been improved by molecular imaging, but cost and clinical utility are still hindrances et al., 2023). The development of AI algorithms and molecular imaging techniques must be improved for wider clinical usage (Weissleder et al., 2016). Biomarker-based precision radiotherapy also has great potential in breast cancer but requires further research in clinical practice (Meehan et al., 2020). Biomarkers based on imaging are also essential in determining immunotherapy response, though standardization is a problem (Wu et al., 2019), as can be seen in Table 1.

Natural Resources for Human Health
eISSN: 2583-1194

MATERIALS AND METHODS

Finding Data:

Systematic searching was performed on PubMed, Scopus, and Google Scholar using keywords associated with pharmacological interventions, radiological methods, and oncology, restricting studies to those published since 2010.

Data Gathering:

Studies were chosen according to their emphasis on pharmacological therapy, radiology, and oncology, with a preference for original studies, clinical trials, and systematic reviews. Researches involving the interface of pharmacology and radiology in the treatment of cancer alone were taken into consideration.

Data Extraction:

Relevant data on study aims, methods, results, and conclusions were gathered, focusing on radiopharmacology, radiotheranostics, and individualized treatment outcomes.

Merging Data:

Data were synthesized qualitatively to develop meaningful patterns in treatment efficacy, integration issues, and emerging frontiers, illuminating the evolving nature of oncology treatments.

Result

Advances in Pharmacological and Radiological Techniques of Oncology Diagnosis and Treatment

With rapid development in oncology, pharmacological treatment and radiological modalities have also experienced revolutionary development. Cancer therapies have been traditionally based on chemotherapy, radiation therapy, and surgery (Healthcare et al., 2024). New and sophisticated specialized modalities have developed in the past decades, such as target therapies, immunotherapies, and gene therapies (Pulumati et al., 2023). These modalities address the molecular features of tumours and cancer cells, enabling more selective treatment with fewer side effects. Radiological modalities have also experienced spectacular development, especially in imaging systems, e.g., PET, CT, MRI, and the production of radiopharmaceuticals. Such systems enable accurate tumour localization, staging, and effective cancer monitoring (Wagner & Conti, 1991).

The combination of radiology and pharmacology is revolutionizing the diagnosis and therapy of cancer. The imaging techniques currently available enable early diagnosis and real-time observations of tumour dynamics (Liu et al., 2019). It empowers the clinicians to follow the course of therapy and choose the course of therapy. High-tech imaging combined with pharmacology treatments enables personalized therapeutic protocols to be developed (Arslan et al., 2024). The result is enhanced and accurate therapy plans, better patient care, and diminished side effects, ultimately making the clinical processes effective and patient care enhanced, as illustrated in Table 2.

New Frontiers in Radiopharmacology: Targeted Drug Delivery and Radiotheranostics for Cancer Therapy

Radiopharmacology is a new blend of pharmacology and radiology, and it has been a powerful tool for cancer treatment. Radiopharmacology is a new science that enables direct delivery of therapeutic agents to tumour cells with minimal damage to surrounding healthy tissues (Varghese et al., 2024). With the power of pharmacology and radiology, radiopharmacology employs radiolabeled drugs that can image and treat tumours. Radiotheranostics is one of the most promising developments in this field, where radiolabeled drugs are used for imaging the molecular composition of tumours and administering therapeutic radiation to the tumour cells (tumour et al., 2021). One of the most notable examples of the two-way application of this approach is the treatment of prostate cancer and neuroendocrine tumours, where radiolabeled agents enable clinicians to image and treat tumours simultaneously. The specificity provided by radiopharmacology minimizes the collateral damage typical of traditional cancer therapies, such as chemotherapy (Dhoundiyal et al., 2024). This leads to improved tumour targeting and therapeutic effects and minimizes the risk of damage to healthy tissues. As science continues to advance, the ongoing application of radiopharmacology will enable increasingly individualized treatment regimens, improving the overall effectiveness of cancer treatments and patients' quality of life (Sgouros et al., 2020), as illustrated in Table 3.

Personalized Oncology: Intersection of Pharmacologic Therapies and Radiologic Advances in Search of Enhanced Outcomes

The integration of radiologic technology and pharmacotherapy gives the basis of individualized oncology. Individualized oncology has evolved beyond the jack-of-all-trades model. Individualized oncology is worried about personalizing treatment to individual patient's genetic history and the nature of cancer in every patient (Marques et al., 2024). Genetic analysis and molecular diagnostics have reached an advanced point such that oncologists can select the best drug therapy regimen based on the tumour profile of individual patients. One of the pioneer developers of precision medicine is this pharmacological therapy-matched personalized radiology (Casà et al., 2023). Sophisticated imaging techniques such as molecular imaging allow oncologists to visualize and investigate tumours' genetic profiles in real time. The imaging techniques give cues that directly influence pharmacological treatment; the selected treatment best corresponds to the patient's tumour profile (Chetty et al., 2015). For example, integrating immune checkpoint inhibitors with radiologic techniques helps better assess tumour response and, hence, translates into improved clinical outcomes and avoidance of unwanted side effects (Rehan, 2024). This is in the direction of more personalized cancer treatment, acquiring information about individual response to therapy and improved long-term prognosis, as in Table 4.

Clinical Trials of Combined Pharmacological and Radiological Therapies in Oncology

Clinical trials are significant for establishing the efficacy of combining radiological and pharmacological approaches in oncology. Over the last few years, many trials of the combination of drug therapy, i.e., immunotherapy, chemotherapy, and targeted therapy with new radiological techniques, i.e., molecular imaging and radiotherapy, have been conducted. Already, experience has shown that the combined techniques improved the efficacy of cancer treatment, allowing clinicians to modify the regimens of treatment based on real-time imaging findings and molecular testing (Jin et al., 2022).

As a specific example, clinical trials employing the combination of radiolabeled drugs and chemotherapy or immunotherapy have proven effective for the therapy of cancer such as prostate, breast, or melanoma cancers. These clinical trials have already provided evidence of the efficacy of radiopharmaceuticals for creating diagnostic and therapeutic effects. Clinicians can quantify the therapeutic response of a tumour to a given therapy with the same drug and tailor the treatment modality accordingly due to the use of the same drug in both imaging and therapy. Problems with standardizing therapy, patient selection, and the addition of side effects still exist. More clinical trials should be performed to eliminate these issues and realize the maximum potential of the combination of drug therapy and advanced radiologic methodologies in oncology (van den Bulk et al., 2018).

Impact of Molecular Imaging and Biomarkers on Monitoring of Cancer Treatment of Cytokine Response

Precision medicine relies on biomarkers and molecular imaging. The new imaging modalities enable tumour imaging at the cellular and molecular levels, enabling cancer detection early in the disease process, tumour growth, and assessment of response to treatment. Imaging modalities such as PET, CT, and MRI enable tumour imaging of metabolism at high resolution, enabling clinicians to precisely measure tumour response to therapy. The modalities are used to detect tumour recurrence or metastasis earlier than conventional modalities permit, enabling optimization of therapy (Folkman, 1990). In addition to imaging agents, biomarkers such as genetic, proteomic, and metabolic markers play a vital role in monitoring and forecasting a response to cancer therapy. Analysis of biomarkers allows clinicians to identify better if the tumour is responding to pharmacologic treatment and can be treated more selectively. For instance, molecular imaging methods and biomarkers are currently available to foretell responses to immune checkpoint inhibitors and targeted treatment. The technologies allow oncologists to design more individualized and targeted therapy protocols, optimizing the efficacy and safety of cancer treatment (Zirlik & Duyster, 2018).

Table 1: Key Literature on Pharmacological and Radiological Integration in Oncology

Authors (Year)	Key Finding	Research Focus	Challenges/Limitations	Future Directions
Abi-Jaoudeh et al. (2013)	Personalized oncology in interventional radiology	Interventional radiology in	Limited clinical integration	Expansion of personalized radiology techniques

		personalized oncology		
Sollini et al. (2020)	AI and hybrid imaging for personalized oncology	Hybrid imaging and AI applications	AI scalability and integration	Improvement of AI algorithms for enhanced precision
Bai et al. (2023)	Molecular imaging in cancer-targeted therapy	Support for cancer-targeted therapies	High cost and limited clinical application	Development of cost-effective, broadly applicable imaging strategies
Weissleder et al. (2016)	Molecular imaging to optimize therapies	Enhancement of therapeutic outcomes	Complexity of molecular therapy optimization	Further optimization of molecular imaging techniques
Meehan et al. (2020)	Role of biomarkers in radiotherapy for breast cancer	Precision medicine in radiotherapy	Difficulty implementing biomarker-based treatments	More research on biomarker-guided radiotherapy
Wu et al. (2019)	Imaging biomarkers for cancer immunotherapy response	Evaluation of immunotherapy responses	Lack of standardized imaging biomarkers	Development of standardized biomarkers for immunotherapy

Legend: This table summarizes significant studies on integrating pharmacology and radiology in oncology, highlighting key findings, research focus, challenges, and future directions.

Table 2: Advances in Radiological Techniques for Cancer Diagnosis and Treatment

Authors (Year)	Key Finding	Research Focus	Challenges/Limitations	Methodology	Future Scope
Healthcare JH (2024)	Advances in radiological cancer diagnosis	Latest imaging technologies	Limited accessibility and integration	Narrative review	Integration of imaging with personalized treatments
Pulumati A (2023)	Technological advancements in diagnostics	Overview of diagnostic methods	Cost, implementation, and technological limitations	Review of advancements	Exploring cost-effective technologies
Wagner Jr HN (1991)	Evolution of medical imaging	Progression in imaging techniques	Outdated methods for current treatments	Review	Enhancing imaging for personalized cancer care
Liu et al. (2019)	Radiomics in precision diagnosis	Radiomics' impact on cancer care	Data complexity and integration issues	Research study	AI integration for better diagnosis and prognosis
Arslan M (2024)	Radiology's role in breast cancer diagnosis	Review of breast cancer care methods	Incomplete understanding of treatment outcomes	Comprehensive review	Advanced imaging technologies in breast cancer treatment

Legend: This table provides a summary of recent findings on radiological advancements in cancer diagnosis and treatment, focusing on challenges and future directions.

Table 3: Key Studies on Radiopharmaceuticals in Cancer Therapy

Authors (Year)	Key Findings	Research Focus	Challenges/Limitations	Regulatory Perspectives	Future Directions
Varghese et al. (2024)	Radiopharmaceuticals in modern therapy	Radiopharmaceutical role in cancer treatment	Need for better precision in targeting	Regulatory frameworks for radiopharmaceuticals	Expanding personalized treatments with radiopharmaceuticals
Kaushik et al. (2021)	Advances in radiopharmaceuticals	Medical uses of radiopharmaceuticals	Regulatory hurdles and approval processes	Regulatory challenges	Expanding medical applications of radiopharmaceuticals
Dhoundiyal et al. (2024)	Radiopharmaceuticals in precision medicine	Precision medicine with radiopharmaceuticals	Accessibility and affordability challenges	Regulatory issues	Expanding use in precision medicine
Sgouros et al. (2020)	Advances in radiopharmaceutical therapy	Clinical application and challenges	Side effects and efficacy concerns	Regulatory challenges	Clinical trial improvements and future advancements

Legend: This table outlines key studies on radiopharmaceuticals, their therapeutic applications, challenges, regulatory perspectives, and future prospects in cancer treatment.

Table 4: Innovative Approaches in Personalized Oncology: AI, In Silico, and Radiation Technology

Authors (Year)	Key Findings	Research Focus	Pharmacological Therapies	Radiological Innovations	Future Directions
Marques et al. (2024)	In silico approaches in drug development	Use of computational models in pharmacology	Personalized drug formulations based on modeling	Integration with radiation therapy planning	Expanding computational platforms for personalized drug development
Chetty et al. (2015)	Innovations in radiation oncology	New radiation techniques	Advances in radiation therapy for personalized care	Improved imaging and radiation delivery	AI-driven improvements in treatment planning
Casà et al. (2023)	Combining art and technology in radiation care	Interdisciplinary approaches in radiation oncology	Targeted therapies and personalized care	Accurate dose delivery and patient-specific treatments	AI and machine learning for individualized care
Rehan (2024)	AI-driven personalized medicine and cloud data	AI in personalized cancer therapy	AI-enhanced drug therapy	AI-supported radiological techniques for monitoring	Real-time treatment adjustments using AI and cloud platforms

Legend: This table summarizes innovative personalized oncology approaches, including in silico drug development, radiation technology, and AI integration, highlighting current applications and future directions in precision medicine.

Challenges and Future Directions towards Integration of Pharmacology with Radiological Advances in Oncology

While incredible advances have occurred in integrating pharmacology and radiologic techniques in oncology, issues still must be overcome. One of these is the issue of the design of personalized regimens of treatment based on molecular profiles unique to the patient due to heterogeneity among protocols to integrate pharmacologic treatment and radiologic imaging. To this is added the inherent heterogeneity of cancer, and it is challenging to predict the tumour's and patient's response to combination treatment (Graig et al., 2016). More advanced drug delivery systems, especially in radiopharmacology, are the focus of ongoing studies with objectives of achieving maximum specificity of targeting and a minimum of systemic toxicity. The availability and cost of newer imaging equipment are also hurdles in translating into the clinic.

Nevertheless, the prospects of the fusion of pharmacology and radiology are bright. Technical advances in imaging biomarkers, drug delivery platforms, and AI-assisted treatment planning and monitoring have vast potential to overcome these challenges. These goals will enhance cancer therapy and its personalization, ultimately converting to better patient outcomes and resultant advancement in oncology (Seddon & Workman, 2003).

DISCUSSION

The marriage of pharmacologic therapy with radiologic methods has propelled oncology to a new cancer treatment and staging frontier. The new model integrates personalized therapy and advanced imaging modalities to optimize treatment specificity and patient advantage (Rudin & Weissleder, 2003). In contrast to the original paradigm of one-size-fits-all chemotherapy, radiation, and surgery, new treatments are increasingly individualized to address tumours' distinctive genetic and molecular features. Pharmacologic innovations now may take the shape of targeted therapy, immunotherapy, and gene therapy so that clinicians may individualize treatments for optimal minimal systemic toxicity and optimal efficacy (Willmann et al., 2008).

Targeted therapies have revolutionized cancer management by treating cancer cell molecular abnormalities and preserving normal tissue. The unprecedented potency of immunotherapies, at least partially in heretofore thought refractory cancers such as melanoma and non-small-cell lung cancer, most accurately describe the revolution that may be attained through personalized oncology. In addition, although still experimental, gene therapies promise to reprogram the tumour's genetic map with long-term durable response implications (Falconi et al., 2014).

Parallel to progress in cancer treatment, radiological progress, particularly molecular imaging, has been a key player in cancer management. Techniques like positron emission tomography (PET), computed tomography (CT), and magnetic resonance imaging (MRI) enable accurate imaging of tumours with high spatial resolution, accurate staging, and real-time monitoring of the disease (Ullal et al., 2014). Progress in radiopharmacology, combining pharmacology and radiological techniques, is a giant leap. Radiopharmaceuticals enable tumour localization, and targeted radiation can be administered to tumour cells with sparing overlying normal cells. Radiotheranostics, the new field of diagnostic imaging and therapeutic radiation integration, is highly useful in neuroendocrine tumours and prostate cancer, where imaging and treatment are delivered concurrently (Lin et al., 2015).

The full potential of these innovations lies in personalized oncology, where genetic analysis and high-tech molecular diagnostics allow oncologists to create highly individualized treatment programs. By integrating radiological imaging, physicians can image and measure the genetic and metabolic fingerprints of tumours and use them in the modulation of pharmacologic therapies. This bidirectional communication optimizes the therapy and minimizes the side effects by enabling the therapies to adapt based on the patient's specific requirements (Frei et al., 2016). Clinical trials have already presented strong evidence for combining pharmacologic treatment and radiological therapy. Experiments in the use of radiolabeled drugs in combination with chemotherapy or immunotherapy have yielded improved therapeutic effects in cancers such as prostate cancer and melanoma. There are limitations, albeit more so in the patient's selection, treatment standardization, and control of side effects (Li et al., 2012).

Despite these obstacles, molecular imaging convergence with radiology and pharmacology is a crucial advancement of precision oncology. Molecular imaging biomarkers are a key consideration in determining the response to treatment and predicting the treatment outcome to create adaptive treatment plans that consider changing real-time tumour growth. However, the widespread use of these techniques in routine practice is forestalled at their expense and with restricted access to state-of-the-art imaging technology (Gasparini & Longo, 2012).

In the coming times, these hurdles must be crossed to reach the maximum integration of pharmacology and radiology. Developments in sophisticated drug delivery systems, enhanced imaging biomarkers, and compatibility with artificial intelligence will be the driving force behind reaching personalized oncology. AI will augment image analysis, help with treatment planning, and allow real-time therapy modulation. With these hurdles crossed, oncology can evolve into more specific, efficient, and personalized therapy, finally leading to improved patient survival and quality of life (Kalia, 2013). This coming together of radiology and pharmacology is the start of a new era in cancer treatment, an era of precision, customization, and improved outcomes.

CONCLUSION:

The combination of pharmacologic treatments and radiologic technology in cancer management represents a revolution in oncology. With the introduction of personalized pharmacologic treatments and radiopharmaceutical and imaging technology, clinicians can provide patients with more potent, targeted, and personalized treatments. The combined approach enhances diagnosis, staging, treatment planning and therapeutic response, minimizes side effects, and ultimately enhances patient outcomes. With advancing technology, combining pharmacology and radiology will shape the future of precision oncology and enhance cancer management.

Key Take aways

The convergence of pharmacological and radiological advances in cancer provides more accurate, targeted therapies, which enhance patient outcomes. Radiotheranostics and radiopharmacology are the keys to delivering tumours with high specificity and minimal collateral damage. Molecular imaging facilitates personalized oncology and helps create individualized treatment plans. Clinical trials hold out the promise of integrating these approaches, though there are challenges of standardization and accessibility. Future research will further simplify integration, spur innovation and improve therapeutic outcomes for cancer patients.

Ethical Concerns

This review abides by the ethical standards of academic honesty in reporting an accurate reflection of research outcomes and proper documentation of sources.

Acknowledgements

We appreciate the researchers and institutions whose work allowed this review to be created.

Conflict of Interest

The authors declare no conflict of interest.

Funding

No funds were specifically earmarked for undertaking this study.

REFERENCE:

[1] Astaraki, M., Wang, C., Buizza, G., et al 2019. Early survival prediction in non-small cell lung cancer from PET/CT images using an intra-tumor partitioning method. Phys Med, 60, 58–65.

[2] Baek, S., He, Y., Allen, B. G., et al 2019. Deep segmentation networks predict the survival of non-small cell lung cancer. Sci Rep, 9(1), 17286.

[3] Bailly, C., Bodet-Milin, C., Couespel, S., et al 2016. Revisiting the robustness of PET-based textural features in the context of multi-centric trials. PLoS One, 11(7), e0159984.

[4] Blanc-Durand, P., Campedel, L., Mule, S., et al 2020. Prognostic value of anthropometric measures extracted from whole-body CT using deep learning in patients with non-small-cell lung cancer. Eur Radiol, 30(6), 3528–3537.

[5] Brown, J. S., Holmes, J. H., Shah, K., et al 2010. Distributed health data networks: A practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Med Care, 48(6 Suppl), S45–S51.

[6] Guaitoli, G., et al 2019. Are we ready to describe response or progression to immunotherapy in lung cancer? Crit Rev Oncol Hematol, 138, 112–119.
[7] Weissleder, R., & Mahmood, U. 2001. Molecular imaging. Radiology, 219, 316–333.
[8] Thakur, M., & Lentle, B. C. 2006. Report of a summit on molecular imaging. AJR Am J Roentgenol, 186, 297–299.
[9] Zhong, L., et al 2021. Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives. Signal Transduct Target Ther, 6, 201.
[10] Abi-Jaoudeh, N., Duffy, A. G., Greten, T. F., et al 2013. Personalized oncology in interventional radiology. J Vasc Interv Radiol, 24(8), 1083–1092.
[11] Sollini, M., Bartoli, F., Marciano, A., et al 2020. Artificial intelligence and hybrid imaging: The best match for personalized medicine in oncology. Eur J Hybrid Imaging, 4, 1–22.
[12] Bai, J. W., Qiu, S. Q., Zhang, G. J., et al 2023. Molecular and functional imaging in cancer-targeted therapy. Signal Transduct Target Ther, 8(1), 89.
[13] Weissleder, R., Schwaiger, M. C., Gambhir, S. S., et al 2016. Imaging approaches to optimize molecular therapies. Science Translational Medicine, 8(355), 355ps16.
[14] Meehan, J., Gray, M., Martínez-Pérez, C., et al 2020. Precision medicine and the role of biomarkers of radiotherapy response in breast cancer. Front Oncol, 10, 628.
[15] Wu, M., Zhang, Y., Zhang, Y., et al 2019. Imaging-based biomarkers for predicting and evaluating cancer immunotherapy response. Radiol Imaging Cancer, 1(2), e190031.
[16] Health (NY)care, J. H., Ali, Z., Hamdoun, A., et al 2024. Advances in radiological techniques for cancer diagnosis. Health (NY), 2(1), 43–56.
[17] Pulumati, A., Pulumati, A., Dwarakanath, B. S., et al 2023. Technological advancements in cancer diagnostics. Cancer Rep, 6(2), e1764.
[18] Wagner, H. N. Jr, & Conti, P. S. 1991. Advances in medical imaging for cancer diagnosis. Cancer, 67(S4), 1121–1128.
[19] Liu, Z., Wang, S., Dong, D., et al 2019. Applications of radiomics in precision diagnosis. Theranostics, 9(5), 1303.
[20] Arslan, M., Asim, M., Sattar, H., et al 2024. Role of radiology in breast cancer diagnosis and treatment. Cureus, 16(9).
[21] Varghese, T. P., John, A., Mathew, J., et al 2024. Radiopharmaceuticals in modern cancer therapy. Precis Radiat Oncol, 8(3), 145–152.
[22] Kaushik, D., Jangra, P., Verma, R., et al 2021. Radiopharmaceuticals: An insight into the latest advances in medical uses and regulatory perspectives. J Biosci, 46, 1–25.
[23] Dhoundiyal, S., Srivastava, S., Kumar, S., et al 2024. Radiopharmaceuticals: Navigating the frontier of precision medicine and therapeutic innovation. Eur J Med Res, 29(1), 26.
[24] Sgouros, G., Bodei, L., McDevitt, M. R., et al 2020. Radiopharmaceutical therapy in cancer: Clinical advances and challenges. Nat Rev Drug Discov, 19(9), 589–608.
[25] Marques, L., Costa, B., Pereira, M., et al 2024. Advancing precision medicine: A review of innovative in silico approaches for drug development, clinical pharmacology, and personalized healthcare. Pharmaceutics, 16(3), 332.
[26] Casà, C., Dinapoli, L., Marconi, E., et al 2023. Integration of art and technology in personalized radiation oncology care: Experiences, evidence, and perspectives. Front Public Health (NY), 11, 1056307.
[27] Chetty, I. J., Martel, M. K., Jaffray, D. A., et al 2015. Technology for innovation in radiation oncology. Int J Radiat Oncol Biol Phys, 93(3), 485–492.
[28] Rehan, H. 2024. Advancing cancer treatment with AI-driven personalized medicine and cloud-based data integration. J Mach Learn Pharm Res, 4(2), 1–40.
[29] Jin, S., et al 2022. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther, 7, 39.
[30] van den Bulk, J., Verdegaal, E. M., & de Miranda, N. F. 2018. Cancer immunotherapy: Broadening the scope of targetable tumors. Open Biol, 8, 180037.
[31] Folkman, J. 1990. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst, 82, 4–6.
[32] Zirlik, K., & Duyster, J. 2018. Anti-angiogenics: Current situation and future perspectives. Oncol Res Treat, 41, 166–171.
[33] Graig, L. A., Phillips, J. K., & Moses, H. L. 2016. Biomarker tests for molecularly targeted therapies—Key to unlocking precision medicine. The National Academies Press, Washington, DC.

eISSN: 2583-1194

[34] Seddon, B. M., & Workman, P. 2003. The role of functional and molecular imaging in cancer drug discovery and development. Br J Radiol, 76(suppl. 2), S128–S138.
[35] Rudin, M., & Weissleder, R. 2003. Molecular imaging in drug discovery and development. Nat Rev Drug Discov, 2, 123–131.
[36] Willmann, J. K., van Bruggen, N., Dinkelborg, L. M., et al 2008. Molecular imaging in drug development. Nat Rev Drug Discov, 7, 591–607.
[37] Falconi, A., Lopes, G., Parker, J. L., et al 2014. Biomarkers and receptor-targeted therapies reduce clinical trial risk in non-small-cell lung cancer. Journal of Thoracic Oncology, 9, 163–169.
[38] Ullal, A. V., Peterson, V., Agasti, S. S., et al 2014. Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. Science Translational Medicine, 6, 219ra9.
[39] Lin, J.-R., Fallahi-Sichani, M., & Sorger, P. K. 2015. Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method. Nat Commun, 6, 8390.
[40] Frei, A. P., Bava, F.-A., Zunder, E. R., et al 2016. Highly multiplexed simultaneous detection of RNAs and proteins in single cells. Nat Methods, 13, 269–275.
[41] Li, J., Chen, F., Cona, M. M., et al 2012. A review of various targeted anticancer therapies. Target Oncol, 7, 69–85. [PubMed: 22350489]
[42] Gasparini, G., & Longo, R. 2012. The paradigm of personalized therapy in oncology. Expert Opin Ther Targets, 16(suppl 1), S7–S16. [PubMed: 22073968]
[43] Kalia, M. 2013. Personalized oncology: Recent advances and future challenges. Metabolism, 62(suppl 1), S11–S14. [PubMed: 22999010]